The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://nicolasmdip978316.jaiblogs.com/66018177/glp-3-retatrutide-a-comparative-analysis